BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg. 1999;229:303-308. [PMID: 10077040 DOI: 10.1097/00000658-199903000-00001] [Cited by in Crossref: 179] [Cited by in F6Publishing: 162] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Yamazaki H, Sugino K, Katoh R, Matsuzu K, Masaki C, Akaishi J, Hames KY, Tomoda C, Suzuki A, Ohkuwa K, Kitagawa W, Nagahama M, Rino Y, Ito K. Response to neoadjuvant paclitaxel predicts survival in anaplastic thyroid carcinoma. Cancer Med 2022. [PMID: 36052510 DOI: 10.1002/cam4.5219] [Reference Citation Analysis]
2 Xie JW, Lu J, Xu BB, Zheng CH, Li P, Wang JB, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Truty MJ, Huang CM. Prognostic Value of Tumor Regression Grading in Patients Treated With Neoadjuvant Chemotherapy Plus Surgery for Gastric Cancer. Front Oncol 2021;11:587856. [PMID: 34386413 DOI: 10.3389/fonc.2021.587856] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Chen Y, Yuan F, Wang L, Li E, Xu Z, Wels M, Yao W, Zhang H. Evaluation of dual-energy CT derived radiomics signatures in predicting outcomes in patients with advanced gastric cancer after neoadjuvant chemotherapy. Eur J Surg Oncol 2021:S0748-7983(21)00635-1. [PMID: 34304951 DOI: 10.1016/j.ejso.2021.07.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chen Y, Wei K, Liu D, Xiang J, Wang G, Meng X, Peng J. A Machine Learning Model for Predicting a Major Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer. Front Oncol 2021;11:675458. [PMID: 34141620 DOI: 10.3389/fonc.2021.675458] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
5 Pelc Z, Skórzewska M, Rawicz-Pruszyński K, Polkowski WP. Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective. Cancers (Basel) 2021;13:2509. [PMID: 34065596 DOI: 10.3390/cancers13102509] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Tsuchida K, Sato T, Aoyama T, Atsumi Y, Kano K, Maezawa Y, Kazama K, Numata M, Yamada T, Tamagawa H, Murakami H, Oshima T, Saeki H, Cho H, Yukawa N, Yamamoto Y, Masuda M, Rino Y. Short-term results of a phase II study of preoperative docetaxel/cisplatin/S-1 therapy for locally advanced gastric cancer. Jpn J Clin Oncol 2021;51:371-8. [PMID: 33283236 DOI: 10.1093/jjco/hyaa221] [Reference Citation Analysis]
7 Rajabnejad A, Vaida F, Valasek M, Razzaque S, Fanta P, Horgan S, Bouvet M, Lowy AM, Kelly KJ. Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer. J Surg Oncol 2021;123:1716-23. [PMID: 33735448 DOI: 10.1002/jso.26458] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Lumish MA, Tarazona N, Janjigian YY. Postoperative ctDNA monitoring: a canary in a coalmine. Ann Oncol 2021;32:431-3. [PMID: 33484835 DOI: 10.1016/j.annonc.2021.01.005] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
9 Ucar G, Acikgoz Y, Ergun Y, Eren T, Dirikoc M, Esen SA, Yazıcı O, Uncu D, Ozdemir NY. Prognostic and Predictive Value of NAR Score in Gastric Cancer. J Gastrointest Cancer 2021;52:1054-60. [PMID: 33064272 DOI: 10.1007/s12029-020-00537-2] [Reference Citation Analysis]
10 Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer 2020;20:313-27. [PMID: 33024587 DOI: 10.5230/jgc.2020.20.e29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
11 Fujitani K, Nakamura K, Mizusawa J, Kuwata T, Shimoda T, Katayama H, Kushima R, Taniguchi H, Yoshikawa T, Boku N, Terashima M, Fukuda H, Sano T, Sasako M; Stomach Cancer Study Group of Japan Clinical Oncology Group (JCOG), Japan. Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A. Gastric Cancer 2021;24:197-204. [PMID: 32572792 DOI: 10.1007/s10120-020-01098-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Kwong MLM, Denham L, Selleck MJ, Kim C, Kunihira K, Kubba R, Rojas R, Garberoglio C, Senthil M. Response to Neoadjuvant Treatment is Influenced by Grade in Gastric Cancer. The American Surgeon 2019;85:1419-22. [DOI: 10.1177/000313481908501241] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
13 Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Mansfield P, Ajani JA, Badgwell BD. Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. J Gastrointest Surg 2021;25:1380-7. [PMID: 32542556 DOI: 10.1007/s11605-020-04688-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
14 Stark AP, Estrella JS, Chiang YJ, Das P, Minsky BD, Blum Murphy MA, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol 2020;122:422-32. [PMID: 32462681 DOI: 10.1002/jso.25984] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
15 Chen Y, Xiao J, Chen X, Wang H, Liu D, Xiang J, Peng J. Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. WJG 2020;26:2426-38. [DOI: 10.3748/wjg.v26.i19.2426] [Reference Citation Analysis]
16 Chen YH, Xiao J, Chen XJ, Wang HS, Liu D, Xiang J, Peng JS. Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. World J Gastroenterol 2020; 26(19): 2427-2439 [PMID: 32476803 DOI: 10.3748/wjg.v26.i19.2427] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
17 Wang K, Yi J, Huang X, Qu Y, Luo J, Xiao J, Zhang S, Tang Y, Liu W, Xu G, Gao L, Xu Z, Liu S, Wang X. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study. Radiat Oncol 2019;14:225. [PMID: 31831042 DOI: 10.1186/s13014-019-1428-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
18 Sánchez-izquierdo N, Perlaza P, Pagès M, Buxó E, Rios J, Rubello D, Colletti PM, Mayoral M, Casanueva S, Fernández-esparrach G, Ginés A, Fuster D. Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma. Clin Nucl Med 2020;45:38-43. [DOI: 10.1097/rlu.0000000000002840] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
19 Wang X, Li X, Zhou N, Zhong D, Bai C, Zhao L. Graded histologic response after neoadjuvant chemotherapy is an optimal criterion for treatment change in patients with locally advanced gastric cancer. Ann Transl Med 2019;7:546. [PMID: 31807528 DOI: 10.21037/atm.2019.09.82] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Derieux S, Svrcek M, Manela S, Lagorce-Pages C, Berger A, André T, Taieb J, Paye F, Voron T. Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandard's Tumor Regression Grade (TRG) in gastric adenocarcinoma. Dig Liver Dis 2020;52:107-14. [PMID: 31427088 DOI: 10.1016/j.dld.2019.07.010] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
21 Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, Blum MM, Ajani JA, Mansfield P, Badgwell BD. Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Ann Surg Oncol 2019;26:3602-10. [PMID: 31350645 DOI: 10.1245/s10434-019-07638-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
22 Rawicz-Pruszyński K, Mielko J, Ciseł B, Skórzewska M, Pikuła A, Gęca K, Skoczylas T, Kubiatowski T, Kurylcio A, Polkowski WP. Blast from the past: Perioperative use of the Maruyama computer program for prediction of lymph node involvement in the surgical treatment of gastric cancer following neoadjuvant chemotherapy. Eur J Surg Oncol 2019;45:1957-63. [PMID: 31178298 DOI: 10.1016/j.ejso.2019.06.001] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Liu W, Li Y, Zhu H, Pei Q, Tan F, Song X, Zhou Z, Zhou Y, Wang D, Pei H. The Relationship between Primary Gross Tumor Volume and Tumor Response of Locally Advanced Rectal Cancer: pGTV as a More Accurate Tumor Size Indicator. J Invest Surg 2021;34:181-90. [PMID: 31116055 DOI: 10.1080/08941939.2019.1615153] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
24 Hayashi M, Yoshikawa T, Yura M, Otsuki S, Yamagata Y, Morita S, Katai H, Nishida T. Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy? Gastric Cancer 2019;22:1274-84. [PMID: 30945120 DOI: 10.1007/s10120-019-00957-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Liu F, Zhou R, Jiang F, Liu G, Li K, Zhu G. Proposal of a Nomogram for Predicting Survival in Patients with Siewert Type II Adenocarcinoma of the Esophagogastric Junction After Preoperative Radiation. Ann Surg Oncol 2019;26:1292-300. [PMID: 30805805 DOI: 10.1245/s10434-019-07237-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
26 Hu SB, Liu CH, Wang X, Dong YW, Zhao L, Liu HF, Cao Y, Zhong DR, Liu W, Li YL, Gao WS, Bai CM, Shang ZH, Li XY. Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer. World J Surg Oncol 2019;17:3. [PMID: 30606195 DOI: 10.1186/s12957-018-1534-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
27 Wei J, Huang R, Guo S, Zhang X, Xi S, Wang Q, Chang H, Wang X, Xiao W, Zeng Z, Gao Y. ypTNM category combined with AJCC tumor regression grade for screening patients with the worst prognosis after neoadjuvant chemoradiation therapy for locally advanced rectal cancer. Cancer Manag Res. 2018;10:5219-5225. [PMID: 30464619 DOI: 10.2147/cmar.s179151] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
28 Mizrak Kaya D, Nogueras-gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, Bhutani MS, Lee JH, Weston B, Minsky BD, Estrella JS, Blum Murphy MA, Matamoros A, Devine CE, Das P, Badgwell BD, Ajani JA. Potentially curable gastric adenocarcinoma treated without surgery. European Journal of Cancer 2018;98:23-9. [DOI: 10.1016/j.ejca.2018.04.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
29 Heger U, Sisic L, Nienhüser H, Blank S, Hinz U, Haag GM, Ott K, Ulrich A, Büchler MW, Schmidt T. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas. Ann Surg Oncol 2018;25:2418-27. [PMID: 29855828 DOI: 10.1245/s10434-018-6541-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
30 Li Z, Wang Y, Shan F, Ying X, Wu Z, Xue K, Miao R, Zhang Y, Ji J. ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer 2018;21:977-87. [PMID: 29748876 DOI: 10.1007/s10120-018-0830-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
31 Lu C, Cai D, Ma J. Pachymic Acid Sensitizes Gastric Cancer Cells to Radiation Therapy by Upregulating Bax through Hypoxia.Am J Chin Med. 2018;46:875-890. [PMID: 29737213 DOI: 10.1142/S0192415X18500465] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
32 Ikoma N, Estrella JS, Blum M, Das P, Chen HC, Wang X, Fournier K, Mansfield P, Ajani J, Badgwell BD. Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. J Gastrointest Surg 2018;22:1325-33. [PMID: 29679346 DOI: 10.1007/s11605-018-3764-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
33 Li Y, Wei Y, He Q, Wang X, Fan C, Li G. Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Sci Rep 2018;8:6223. [PMID: 29670115 DOI: 10.1038/s41598-018-24259-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
34 Mizrak Kaya D, Harada K, Amlashi FG, Vasilakopoulou M, Ajani JA. Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Dis Transl Med 2018;4:8-17. [PMID: 29756119 DOI: 10.1016/j.cdtm.2018.02.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
35 Zhou J, Shen J, Seifer BJ, Jiang S, Wang J, Xiong H, Xie L, Wang L, Sui X. Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. Oncotarget 2017;8:30477-94. [PMID: 27802185 DOI: 10.18632/oncotarget.12955] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
36 Spoerl S, Novotny A, Al-batran S, Lordick F, Thuss-patience P, Pauligk C, Haller B, Feith M, Lorenzen S. Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. European Journal of Cancer 2018;90:26-33. [DOI: 10.1016/j.ejca.2017.11.020] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
37 Li Z, Shan F, Wang Y, Zhang Y, Zhang L, Li S, Jia Y, Xue K, Miao R, Li Z, Ji J. Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PLoS One 2018;13:e0189294. [PMID: 29370182 DOI: 10.1371/journal.pone.0189294] [Cited by in Crossref: 17] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]
38 Liu J, Su M, Wang J, Zhang G, Zhou J, Zhang A, Ren Z, Zheng X, Hong S, Wang S, Zhang R. A novel grade-lymph node ratio model predicts the prognosis of the advanced gastric cancer patients after neoadjuvant radiotherapy. Oncotarget 2017;8:14058-67. [PMID: 27740935 DOI: 10.18632/oncotarget.12573] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
39 Kochi M, Fujii M, Kanamori N, Mihara Y, Funada T, Tamegai H, Watanabe M, Takayama Y, Suda H, Takayama T. Phase II Study of Neoadjuvant Chemotherapy With S-1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer. Am J Clin Oncol. 2017;40:17-21. [PMID: 24662266 DOI: 10.1097/coc.0000000000000058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
40 Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, Mansfield P, Ajani JA, Badgwell BD. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer 2018;21:74-83. [PMID: 28643144 DOI: 10.1007/s10120-017-0743-4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
41 Ng J, Lee P. The Role of Radiotherapy in Localized Esophageal and Gastric Cancer. Hematology/Oncology Clinics of North America 2017;31:453-68. [DOI: 10.1016/j.hoc.2017.01.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
42 Mieno H, Yamashita K, Hosoda K, Moriya H, Higuchi K, Azuma M, Komori S, Yoshida T, Tanabe S, Koizumi W, Katada N, Watanabe M. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer. Surg Today 2017;47:1249-58. [PMID: 28365892 DOI: 10.1007/s00595-017-1512-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
43 Al-Batran SE, Lorenzen S. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge? Hematol Oncol Clin North Am 2017;31:441-52. [PMID: 28501086 DOI: 10.1016/j.hoc.2017.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
44 Zhu Y, Sun Y, Hu S, Jiang Y, Yue J, Xue X, Yang L, Xue L. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China. BMC Gastroenterol. 2017;17:41. [PMID: 28292272 DOI: 10.1186/s12876-017-0598-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 28] [Article Influence: 3.8] [Reference Citation Analysis]
45 Kodera Y. Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surg Today. 2017;47:899-907. [PMID: 28247105 DOI: 10.1007/s00595-017-1473-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
46 Wang X, Wei Y, Xue Y, Lu P, Yu L, Shen B. Predictive Role of the Number of 18F-FDG-Positive Lymph Nodes Detected by PET/CT for Pre-Treatment Evaluation of Locally Advanced Gastric Cancer. PLoS One 2016;11:e0166836. [PMID: 27936109 DOI: 10.1371/journal.pone.0166836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
47 Fiteni F, Paget-Bailly S, Messager M, N'Guyen T, Lakkis Z, Mathieu P, Lamfichekh N, Picard A, Benzidane B, Cléau D. Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma. Cancer Med. 2016;5:3085-3093. [PMID: 27726290 DOI: 10.1002/cam4.885] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
48 Chang AY, Foo KF, Koo WH, Ong S, So J, Tan D, Lim KH. Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterol 2016;3:e000095. [PMID: 27648294 DOI: 10.1136/bmjgast-2016-000095] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
49 Zhang LN, Xiao WW, Xi SY, OuYang PY, You KY, Zeng ZF, Ding PR, Zhang HZ, Pan ZZ, Xu RH, Gao YH. Pathological Assessment of the AJCC Tumor Regression Grading System After Preoperative Chemoradiotherapy for Chinese Locally Advanced Rectal Cancer. Medicine (Baltimore). 2016;95:e2272. [PMID: 26817863 DOI: 10.1097/md.0000000000002272] [Cited by in Crossref: 8] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
50 Wang X, Zhao L, Liu H, Zhong D, Liu W, Shan G, Dong F, Gao W, Bai C, Li X. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer 2016;114:1326-33. [PMID: 27172250 DOI: 10.1038/bjc.2016.126] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
51 Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gaßler N, Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann I, Lordick F. Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med 2016;5:1444-53. [PMID: 27073068 DOI: 10.1002/cam4.720] [Cited by in Crossref: 32] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
52 Blank S, Knebel P, Haag GM, Bruckner T, Klaiber U, Burian M, Schaible A, Sisic L, Schmidt T, Diener MK, Ott K. Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4 weeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial. Pilot Feasibility Stud 2016;2:18. [PMID: 27965838 DOI: 10.1186/s40814-016-0059-x] [Reference Citation Analysis]
53 Santa-Maria AF, Valadão M, Iglesias AC. The role of staging laparoscopy in treatment of locally advanced gastric cancer. Surg Laparosc Endosc Percutan Tech 2014;24:434-9. [PMID: 24910937 DOI: 10.1097/SLE.0000000000000065] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
54 Aichler M, Motschmann M, Jütting U, Luber B, Becker K, Ott K, Lordick F, Langer R, Feith M, Siewert JR, Walch A. Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget 2014;5:6620-32. [PMID: 25216514 DOI: 10.18632/oncotarget.2268] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
55 Springfeld C, Wiecha C, Kunzmann R, Heger U, Weichert W, Langer R, Stange A, Blank S, Sisic L, Schmidt T, Lordick F, Jäger D, Grenacher L, Bruckner T, Büchler MW, Ott K. Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Ann Surg Oncol 2015;22:905-14. [DOI: 10.1245/s10434-015-4617-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
56 Schulz C, Kullmann F, Kunzmann V, Fuchs M, Geissler M, Vehling-Kaiser U, Stauder H, Wein A, Al-Batran SE, Kubin T. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. Int J Cancer. 2015;137:678-685. [PMID: 25530271 DOI: 10.1002/ijc.29403] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 7.1] [Reference Citation Analysis]
57 Schwarz RE. Current status of management of malignant disease: current management of gastric cancer. J Gastrointest Surg. 2015;19:782-788. [PMID: 25591828 DOI: 10.1007/s11605-014-2707-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
58 Kodera Y, Kobayashi D, Tanaka C, Fujiwara M. Gastric adenocarcinoma with para-aortic lymph node metastasis: A borderline resectable cancer? Surg Today. 2015;45:1082-1090. [PMID: 25366353 DOI: 10.1007/s00595-014-1067-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
59 Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014; 20(33): 11567-11573 [PMID: 25206264 DOI: 10.3748/wjg.v20.i33.11567] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
60 Hashemzadeh S, Pourzand A, Somi MH, Zarrintan S, Javad-Rashid R, Esfahani A. The effects of neoadjuvant chemotherapy on resectability of locally-advanced gastric adenocarcinoma: a clinical trial. Int J Surg. 2014;12:1061-1069. [PMID: 25157992 DOI: 10.1016/j.ijsu.2014.08.349] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
61 Wu A, Jia Y, Dong B, Tang L, Liu Y, Du H, Yuan P, Dong P, Ji J. Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy. Cancer Chemother Pharmacol 2014;73:885-93. [PMID: 24658652 DOI: 10.1007/s00280-014-2410-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
62 Trip AK, Poppema BJ, van Berge Henegouwen MI, Siemerink E, Beukema JC, Verheij M, Plukker JT, Richel DJ, Hulshof MC, van Sandick JW, Cats A, Jansen EP, Hospers GA. Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiother Oncol 2014;112:284-8. [PMID: 24856116 DOI: 10.1016/j.radonc.2014.05.003] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
63 Guo Mg, Zheng Q, zhong Di J, Yang Z. Histological complete response to a combined docetaxel/cisplatin/fluorouracil neoadjuvant chemotherapy for T4 stage gastric adenocarcinoma. World J Surg Oncol 2014;12:150. [PMID: 24885421 DOI: 10.1186/1477-7819-12-150] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
64 Jary M, Ghiringhelli F, Jacquin M, Fein F, Nguyen T, Cleau D, Nerich V, El Gani M, Mathieu P, Valmary-Degano S. Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Cancer Chemother Pharmacol. 2014;74:141-150. [PMID: 24824852 DOI: 10.1007/s00280-014-2482-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
65 Peixoto RD, Cheung WY, Lim HJ. Perioperative chemotherapy for gastroesophageal cancer in British Columbia: a multicentre experience. Curr Oncol 2014;21:77-83. [PMID: 24764696 DOI: 10.3747/co.21.1788] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
66 Wang Y, Yu YY, Li W, Feng Y, Hou J, Ji Y, Sun YH, Shen KT, Shen ZB, Qin XY, Liu TS. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol. 2014;73:1155-1161. [PMID: 24748418 DOI: 10.1007/s00280-014-2449-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 4.9] [Reference Citation Analysis]
67 Schmidt T, Sicic L, Blank S, Becker K, Weichert W, Bruckner T, Parakonthun T, Langer R, Büchler MW, Siewert JR, Lordick F, Ott K. Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. Br J Cancer 2014;110:1712-20. [PMID: 24569472 DOI: 10.1038/bjc.2014.94] [Cited by in Crossref: 64] [Cited by in F6Publishing: 75] [Article Influence: 8.0] [Reference Citation Analysis]
68 Kwee RM, Kwee TC. Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World J Gastroenterol 2014; 20(7): 1650-1656 [PMID: 24587644 DOI: 10.3748/wjg.v20.i7.1650] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
69 Guo Z, Wang X, Lin R, Chen L, Fan N, Chen Y, Lin J, Yu J. Paclitaxel-based regimens as first-line treatment in advanced gastric cancer. J Chemother 2015;27:94-8. [PMID: 24548091 DOI: 10.1179/1973947814Y.0000000169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
70 Blank S, Rachakonda S, Keller G, Weichert W, Lordick F, Langer R, Springfeld C, Bruckner T, Becker K, Kumar R, Ott K. A retrospective comparative exploratory study on two methylentetrahydrofolate reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients. BMC Cancer 2014;14:58. [PMID: 24490800 DOI: 10.1186/1471-2407-14-58] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
71 Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F, Bruckner T, Dobritz M, Burian M, Springfeld C. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol. 2014;21:1739-1748. [PMID: 24419755 DOI: 10.1245/s10434-013-3462-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 53] [Article Influence: 5.9] [Reference Citation Analysis]
72 Sendler A, Siewert JR. Individualizing therapy in gastric cancer. Expert Review of Anticancer Therapy 2014;3:457-70. [DOI: 10.1586/14737140.3.4.457] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
73 Chen W, Shen J, Pan T, Hu W, Jiang Z, Yuan X, Wang L. FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. Exp Ther Med 2014;7:461-7. [PMID: 24396426 DOI: 10.3892/etm.2013.1449] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
74 Jia Y, Ye L, Ji K, Zhang L, Hargest R, Ji J, Jiang WG. Death-associated protein-3, DAP-3, correlates with preoperative chemotherapy effectiveness and prognosis of gastric cancer patients following perioperative chemotherapy and radical gastrectomy. Br J Cancer 2014;110:421-9. [PMID: 24300973 DOI: 10.1038/bjc.2013.712] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
75 Giganti F, De Cobelli F, Canevari C, Orsenigo E, Gallivanone F, Esposito A, Castiglioni I, Ambrosi A, Albarello L, Mazza E. Response to chemotherapy in gastric adenocarcinoma with diffusion-weighted MRI and (18) F-FDG-PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. J Magn Reson Imaging. 2014;40:1147-1157. [PMID: 24214734 DOI: 10.1002/jmri.24464] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 4.1] [Reference Citation Analysis]
76 Luis M, Tavares A, Carvalho LS, Lara-Santos L, Araújo A, Mello RA. Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies. World J Gastroenterol 2013; 19(38): 6383-6397 [PMID: 24151357 DOI: 10.3748/wjg.v19.i38.6383] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
77 Heger U, Bader F, Lordick F, Burian M, Langer R, Dobritz M, Blank S, Bruckner T, Becker K, Herrmann K. Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer. 2013;Sep 1; Epub ahead of print. [PMID: 23996162 DOI: 10.1007/s10120-013-0296-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
78 Blank S, Lordick F, Dobritz M, Grenacher L, Burian M, Langer R, Roth W, Schaible A, Becker K, Bläker H, Sisic L, Stange A, Compani P, Schulze-bergkamen H, Jäger D, Büchler M, Siewert J, Ott K. A reliable risk score for stage IV esophagogastric cancer. European Journal of Surgical Oncology (EJSO) 2013;39:823-30. [DOI: 10.1016/j.ejso.2013.01.005] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
79 Zhang C, Zeng Y, Li H, Zhao Z, Zhang J, Dai D. Neoadjuvant Chemotherapy for Nonmetastatic Esophago-Gastric Adenocarcinomas: A Systematic Review and Meta-Analysis. Cancer Investigation 2013;31:421-31. [DOI: 10.3109/07357907.2013.802801] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
80 Lorenzen S, Thuss-Patience P, Al-Batran SE, Lordick F, Haller B, Schuster T, Pauligk C, Luley K, Bichev D, Schumacher G, Homann N. Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Ann Oncol. 2013;24:2068-2073. [PMID: 23592699 DOI: 10.1093/annonc/mdt141] [Cited by in Crossref: 59] [Cited by in F6Publishing: 61] [Article Influence: 6.6] [Reference Citation Analysis]
81 Ott K, Blank S, Becker K, Langer R, Weichert W, Roth W, Sisic L, Stange A, Jäger D, Büchler M. Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10 % residual tumor. Langenbecks Arch Surg. 2013;398:239-249. [PMID: 23269519 DOI: 10.1007/s00423-012-1039-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
82 Ang J, Hu L, Huang PT, Wu JX, Huang LN, Cao CH, Zheng YX, Chen L. Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. World J Gastroenterol 2012; 18(47): 7026-7032 [PMID: 23323004 DOI: 10.3748/wjg.v18.i47.7026] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
83 Guo T, Yao F, Yang AM, Li XY, Zhong DR, Wu DS, Wu X, Lu XH. Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy. Asia Pac J Clin Oncol. 2012;Dec 21; Epub ahead of print. [PMID: 23279745 DOI: 10.1111/ajco.12045] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
84 Blank S, Stange A, Sisic L, Roth W, Grenacher L, Sterzing F, Burian M, Jäger D, Büchler M, Ott K. Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbecks Arch Surg 2013;398:211-20. [PMID: 23224565 DOI: 10.1007/s00423-012-1034-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
85 Han DS, Suh YS, Kong SH, Lee HJ, Im SA, Bang YJ, Kim WH, Yang HK. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases. J Surg Oncol 2013;107:511-6. [PMID: 23090791 DOI: 10.1002/jso.23284] [Cited by in Crossref: 29] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
86 Goodman KA, Khalid N, Kachnic LA, Minsky BD, Crozier C, Owen JB, Devlin PM, Thomas CR Jr. Quality Research in Radiation Oncology analysis of clinical performance measures in the management of gastric cancer. Int J Radiat Oncol Biol Phys 2013;85:355-62. [PMID: 23040221 DOI: 10.1016/j.ijrobp.2012.08.021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
87 Vercelli M, Lillini R, Capocaccia R, Quaglia A; Socio-Economic Indicators and Health Working Group., AIRTUM Contributors. Use of SERTS (Socio-Economic, health Resources and Technologic Supplies) models to estimate cancer survival at provincial geographical level. Cancer Epidemiol 2012;36:566-74. [PMID: 22906484 DOI: 10.1016/j.canep.2012.07.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
88 Schwarz RE, Mansour JC. The real estate of gastric cancer induction therapy: location versus intrinsic molecular architecture. Ann Surg Oncol 2012;19:2081-3. [PMID: 22535261 DOI: 10.1245/s10434-012-2366-7] [Reference Citation Analysis]
89 Mihaljevic AL, Friess H, Schuhmacher C. Clinical trials in gastric cancer and the future. J Surg Oncol 2013;107:289-97. [PMID: 22514058 DOI: 10.1002/jso.23120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
90 Lorenzen S, Blank S, Lordick F, Siewert JR, Ott K. Prediction of response and prognosis by a score including only pretherapeutic parameters in 410 neoadjuvant treated gastric cancer patients. Ann Surg Oncol. 2012;19:2119-2127. [PMID: 22395980 DOI: 10.1245/s10434-012-2254-1] [Cited by in Crossref: 36] [Cited by in F6Publishing: 37] [Article Influence: 3.6] [Reference Citation Analysis]
91 Jia Y, Dong B, Tang L, Liu Y, Du H, Yuan P, Wu A, Ji J. Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer. Tumour Biol. 2012;33:1151-1158. [PMID: 22383294 DOI: 10.1007/s13277-012-0357-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
92 Fujitani K, Mano M, Hirao M, Kodama Y, Tsujinaka T. Posttherapy nodal status, not graded histologic response, predicts survival after neoadjuvant chemotherapy for advanced gastric cancer. Ann Surg Oncol 2012;19:1936-43. [PMID: 22187120 DOI: 10.1245/s10434-011-2165-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
93 Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu XJ, Wu Q, Zong XL, Ren H, Tang L, Zhang XP, Li JY, Hu Y, Shen L, Ji JF. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2012;105:793-799. [PMID: 22189752 DOI: 10.1002/jso.23009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
94 Reim D, Gertler R, Novotny A, Becker K, zum Büschenfelde CM, Ebert M, Dobritz M, Langer R, Hoefler H, Friess H. Adenocarcinomas of the esophagogastric junction are more likely to respond to preoperative chemotherapy than distal gastric cancer. Ann Surg Oncol. 2012;19:2108-2118. [PMID: 22130620 DOI: 10.1245/s10434-011-2147-8] [Cited by in Crossref: 50] [Cited by in F6Publishing: 51] [Article Influence: 4.5] [Reference Citation Analysis]
95 Patel SH, Kooby DA. Gastric adenocarcinoma surgery and adjuvant therapy. Surg Clin North Am 2011;91:1039-77. [PMID: 21889029 DOI: 10.1016/j.suc.2011.06.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
96 Sbitti Y, Essaidi I, Debbagh A, Kadiri H, Oukabli M, Moussaid Y, Slimani K, Fetohi M, Elkaoui H, Albouzidi A, Mahi M, Ali AA, Ichou M, Errihani H. Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma? World J Surg Oncol 2011;9:112. [PMID: 21955806 DOI: 10.1186/1477-7819-9-112] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
97 Matuschek C, Bölke E, Peiper M, Knoefel WT, Budach W, Erhardt A, Scherer A, Gerber PA, Buhren BA, Gattermann N, Baldus SE, Rusnak E, Shukla V, Orth K. The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. Eur J Med Res 2011;16:265-74. [PMID: 21810561 DOI: 10.1186/2047-783x-16-6-265] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
98 Zheng Z, Yu Y, Lu M, Sun W, Wang F, Li P, Zhang Y, Lin L, Huang P, Chen J. Double contrast-enhanced ultrasonography for the preoperative evaluation of gastric cancer: a comparison to endoscopic ultrasonography with respect to histopathology. Am J Surg. 2011;202:605-611. [PMID: 21824594 DOI: 10.1016/j.amjsurg.2010.09.033] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
99 Ott K, Herrmann K, Schuster T, Langer R, Becker K, Wieder HA, Wester HJ, Siewert JR, zum Büschenfelde CM, Buck AK. Molecular imaging of proliferation and glucose utilization: utility for monitoring response and prognosis after neoadjuvant therapy in locally advanced gastric cancer. Ann Surg Oncol. 2011;18:3316-3323. [PMID: 21537865 DOI: 10.1245/s10434-011-1743-y] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
100 Ott K, Rachakonda PS, Panzram B, Keller G, Lordick F, Becker K, Langer R, Buechler M, Hemminki K, Kumar R. DNA repair gene and MTHFR gene polymorphisms as prognostic markers in locally advanced adenocarcinoma of the esophagus or stomach treated with cisplatin and 5-fluorouracil-based neoadjuvant chemotherapy. Ann Surg Oncol. 2011;18:2688-2698. [PMID: 21347786 DOI: 10.1245/s10434-011-1601-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
101 Ott K, Lordick F, Blank S, Büchler M. Gastric cancer: surgery in 2011. Langenbecks Arch Surg 2011;396:743-58. [PMID: 21234760 DOI: 10.1007/s00423-010-0738-7] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
102 Raphael MF, Kluijt I, Koot BG, Smets AM, Tilanus ME, Bras J, van de Wetering MD. Gastric adenocarcinoma in a 13-year-old boy: a diagnosis not often seen in this age group. Pediatr Hematol Oncol 2011;28:71-7. [PMID: 21083354 DOI: 10.3109/08880018.2010.520820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Wang J, Saukel GW, Garberoglio CA, Srikureja W, Hsueh CT. Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. J Hematol Oncol. 2010;3:31. [PMID: 20828403 DOI: 10.1186/1756-8722-3-31] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
104 Ott K, Lordick F. [Neoadjuvant therapy in the upper gastro-intestinal tract. Gastric cancer from a surgical viewpoint]. Chirurg 2009;80:1028-34. [PMID: 19756431 DOI: 10.1007/s00104-009-1736-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
105 Lorenzen S, Panzram B, Keller G, Lordick F, Herrmann K, Becker K, Langer R, Schwaiger M, Siewert JR, Ott K. Association of the VEGF 936C>T Polymorphism with FDG Uptake, Clinical, Histopathological, and Metabolic Response in Patients with Adenocarcinomas of the Esophagogastric Junction. Mol Imaging Biol 2011;13:178-86. [DOI: 10.1007/s11307-010-0330-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
106 Mezhir JJ, Tang LH, Coit DG. Neoadjuvant therapy of locally advanced gastric cancer. J Surg Oncol. 2010;101:305-314. [PMID: 20187070 DOI: 10.1002/jso.21483] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
107 Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Kokubo K, Kobayashi H, Kim MS, Sidransky D, Watanabe M. Potential utility of HOP homeobox gene promoter methylation as a marker of tumor aggressiveness in gastric cancer. Oncogene. 2010;29:3263-3275. [PMID: 20228841 DOI: 10.1038/onc.2010.76] [Cited by in Crossref: 46] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
108 Ma Y, Qin H, Zheng Q, Wang Y, Wang Z, Yang Z. Neoadjuvant chemotherapy with a combination of docetaxel, cisplatin, fluorouracil, and leucovorin in nonresectable advanced gastric cancer: a short communication. Med Oncol 2010;27:1089-95. [PMID: 19885749 DOI: 10.1007/s12032-009-9340-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
109 Jhawer M, Coit D, Brennan M, Qin LX, Gonen M, Klimstra D, Tang L, Kelsen DP, Shah MA. Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation. Am J Clin Oncol. 2009;32:356-362. [PMID: 19381079 DOI: 10.1097/coc.0b013e31818c08e8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
110 He RB, Chen JQ. Research progress in neoadjuvant chemotherapy for gastric cancer. Shijie Huaren Xiaohua Zazhi 2009; 17(12): 1207-1211 [DOI: 10.11569/wcjd.v17.i12.1207] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
111 Mansour JC, Schwarz RE. Pathologic Response to Preoperative Therapy: Does It Mean What We Think It Means? Ann Surg Oncol 2009;16:1465-79. [DOI: 10.1245/s10434-009-0374-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
112 House MG, Brennan MF. Neoadjuvant therapy for gastric cancer. Adv Surg. 2008;42:151-168. [PMID: 18953815 DOI: 10.1016/j.yasu.2008.04.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
113 Tillman GF, Pawlicki T, Koong AC, Goodman KA. Preoperative versus postoperative radiotherapy for locally advanced gastroesophageal junction and proximal gastric cancers: a comparison of normal tissue radiation doses. Diseases of the Esophagus 2008;21:437-44. [DOI: 10.1111/j.1442-2050.2007.00794.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
114 Persiani R, Rausei S, Pozzo C, Biondi A, Barone C, Cananzi FC, Schinzari G, D’Ugo D. 7-Year survival results of perioperative chemotherapy with epidoxorubicin, etoposide, and cisplatin (EEP) in locally advanced resectable gastric cancer: up-to-date analysis of a phase-II study. Ann Surg Oncol. 2008;15:2146-2152. [PMID: 18543037 DOI: 10.1245/s10434-008-9982-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
115 Ott K, Lordick F, Herrmann K, Krause BJ, Schuhmacher C, Siewert JR. The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer. 2008;11:1-9. [PMID: 18373171 DOI: 10.1007/s10120-007-0448-1] [Cited by in Crossref: 43] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
116 Moehler M, Galle PR, Gockel I, Junginger T, Schmidberger H. The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer. Best Pract Res Clin Gastroenterol 2007;21:965-81. [PMID: 18070698 DOI: 10.1016/j.bpg.2007.10.003] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
117 Ng K, Meyerhardt JA, Fuchs CS. Adjuvant and neoadjuvant approaches in gastric cancer. Cancer J. 2007;13:168-174. [PMID: 17620766 DOI: 10.1097/ppo.0b013e318074e351] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
118 Mansour JC, Tang L, Shah M, Bentrem D, Klimstra DS, Gonen M, Kelsen DP, Brennan MF, Coit DG. Does graded histologic response after neoadjuvant chemotherapy predict survival for completely resected gastric cancer? Ann Surg Oncol. 2007;14:3412-3418. [PMID: 17909917 DOI: 10.1245/s10434-007-9574-6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 83] [Article Influence: 5.0] [Reference Citation Analysis]
119 Yao JC, Ajani JA. Gastric cancer. Curr Opin Gastroenterol 2000;16:516-21. [PMID: 17031130 DOI: 10.1097/00001574-200011000-00009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
120 Nakagawa S, Nashimoto A, Yabusaki H. Role of staging laparoscopy with peritoneal lavage cytology in the treatment of locally advanced gastric cancer. Gastric Cancer. 2007;10:29-34. [PMID: 17334715 DOI: 10.1007/s10120-006-0406-3] [Cited by in Crossref: 73] [Cited by in F6Publishing: 68] [Article Influence: 4.9] [Reference Citation Analysis]
121 Ott K, Weber W, Siewert J. The importance of Pet in the diagnosis and response evaluation of esophageal cancer. Diseases of the Esophagus 2006;19:433-42. [DOI: 10.1111/j.1442-2050.2006.00617.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 48] [Article Influence: 3.4] [Reference Citation Analysis]
122 Ott K, Weber WA, Lordick F, Becker K, Busch R, Herrmann K, Wieder H, Fink U, Schwaiger M, Siewert JR. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698. [PMID: 16966684 DOI: 10.1200/jco.2006.06.7801] [Cited by in Crossref: 339] [Cited by in F6Publishing: 310] [Article Influence: 21.2] [Reference Citation Analysis]
123 D’Ugo D, Persiani R, Rausei S, Biondi A, Vigorita V, Boccia S, Ricci R. Response to neoadjuvant chemotherapy and effects of tumor regression in gastric cancer. Eur J Surg Oncol. 2006;32:1105-1109. [PMID: 16930932 DOI: 10.1016/j.ejso.2006.07.009] [Cited by in Crossref: 26] [Cited by in F6Publishing: 34] [Article Influence: 1.6] [Reference Citation Analysis]
124 Garces CA, McAuliffe PF, Hochwald SN, Cance WG. Neoadjuvant therapy in the treatment of solid tumors. Curr Probl Surg 2006;43:457-551. [PMID: 16860653 DOI: 10.1067/j.cpsurg.2006.04.003] [Reference Citation Analysis]
125 Brenner B, Shah MA, Karpeh MS, Gonen M, Brennan MF, Coit DG, Klimstra DS, Tang LH, Kelsen DP. A phase II trial of neoadjuvant cisplatin-fluorouracil followed by postoperative intraperitoneal floxuridine-leucovorin in patients with locally advanced gastric cancer. Ann Oncol. 2006;17:1404-1411. [PMID: 16788003 DOI: 10.1093/annonc/mdl133] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 2.4] [Reference Citation Analysis]
126 Satoh S, Hasegawa S, Ozaki N, Okabe H, Watanabe G, Nagayama S, Fukushima M, Takabayashi A, Sakai Y. Retrospective analysis of 45 consecutive patients with advanced gastric cancer treated with neoadjuvant chemotherapy using an S-1/CDDP combination. Gastric Cancer 2006;9:129-35. [DOI: 10.1007/s10120-006-0369-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
127 Kodera Y, Fujiwara M, Koike M, Nakao A. Chemotherapy as a component of multimodal therapy for gastric carcinoma. World J Gastroenterol 2006; 12(13): 2000-2005 [PMID: 16610047 DOI: 10.3748/wjg.v12.i13.2000] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
128 Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C. Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer. JCO 2005;23:8688-96. [DOI: 10.1200/jco.2005.02.1329] [Cited by in Crossref: 863] [Cited by in F6Publishing: 846] [Article Influence: 50.8] [Reference Citation Analysis]
129 Gonzalez RJ, Mansfield PF. Adjuvant and neoadjuvant therapy for gastric cancer. Surg Clin North Am. 2005;85:1033-1051, viii. [PMID: 16139035 DOI: 10.1016/j.suc.2005.05.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
130 Lordick F, Siewert JR. Neoadjuvante Therapie beim lokal fortgeschrittenen Magenkarzinom. Onkologe 2005;11:640-9. [DOI: 10.1007/s00761-005-0881-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
131 Harting MT, Blakely ML, Herzog CE, Lally KP, Ajani JA, Andrassy RJ. Treatment issues in pediatric gastric adenocarcinoma. J Pediatr Surg. 2004;39:e8-e10. [PMID: 15300556 DOI: 10.1016/j.jpedsurg.2004.04.043] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
132 White RR, Xie HB, Gottfried MR, Czito BG, Hurwitz HI, Morse MA, Blobe GC, Paulson EK, Baillie J, Branch MS. Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer. Ann Surg Oncol. 2005;12:214-221. [PMID: 15827813 DOI: 10.1245/aso.2005.03.105] [Cited by in Crossref: 123] [Cited by in F6Publishing: 115] [Article Influence: 7.2] [Reference Citation Analysis]
133 Master SS. Gastric carcinoma. Dis Mon 2004;50:532-9. [PMID: 15616487 DOI: 10.1016/j.disamonth.2004.09.002] [Reference Citation Analysis]
134 Hartgrink HH, van de Velde CJ, Putter H, Songun I, Tesselaar ME, Kranenbarg EK, de Vries JE, Wils JA, van der Bijl J, van Krieken JH; Cooperating Investigators of The Dutch Gastric Cancer Group. Neo-adjuvant chemotherapy for operable gastric cancer: long term results of the Dutch randomised FAMTX trial. Eur J Surg Oncol. 2004;30:643-649. [PMID: 15256239 DOI: 10.1016/j.ejso.2004.04.013] [Cited by in Crossref: 126] [Cited by in F6Publishing: 116] [Article Influence: 7.0] [Reference Citation Analysis]
135 Marcus SG, Cohen D, Lin K, Wong K, Thompson S, Rothberger A, Potmesil M, Hiotis S, Newman E. Complications of gastrectomy following CPT-11-based neoadjuvant chemotherapy for gastric cancer. J Gastrointest Surg. 2003;7:1015-1022; discussion 1023. [PMID: 14675711 DOI: 10.1016/j.gassur.2003.09.007] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.1] [Reference Citation Analysis]
136 Cascinu S, Scartozzi M, Labianca R, Catalano V, Silva RR, Barni S, Zaniboni A, D'Angelo A, Salvagni S, Martignoni G. High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer. 2004;90:1521-1525. [PMID: 15083179 DOI: 10.1038/sj.bjc.6601752] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
137 Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91:540-551. [PMID: 15122603 DOI: 10.1002/bjs.4575] [Cited by in Crossref: 78] [Cited by in F6Publishing: 54] [Article Influence: 4.3] [Reference Citation Analysis]
138 Lawrence W. Gastric Adenocarcinoma. Curr Treat Options Gastroenterol 2004;7:149-57. [PMID: 15010029 DOI: 10.1007/s11938-004-0036-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
139 Yao JC, Mansfield PF, Pisters PW, Feig BW, Janjan NA, Crane C, Ajani JA. Combined-modality therapy for gastric cancer. Semin Surg Oncol. 2003;21:223-227. [PMID: 14648779 DOI: 10.1002/ssu.10040] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
140 Wieder HA, Brücher BL, Zimmermann F, Becker K, Lordick F, Beer A, Schwaiger M, Fink U, Siewert JR, Stein HJ. Time course of tumor metabolic activity during chemoradiotherapy of esophageal squamous cell carcinoma and response to treatment. J Clin Oncol. 2004;22:900-908. [PMID: 14990646 DOI: 10.1200/jco.2004.07.122] [Cited by in Crossref: 340] [Cited by in F6Publishing: 305] [Article Influence: 18.9] [Reference Citation Analysis]
141 Roth AD. Curative treatment of gastric cancer: towards a multidisciplinary approach? Crit Rev Oncol Hematol. 2003;46:59-100. [PMID: 12672518 DOI: 10.1016/S1040-8428(02)00160-9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
142 Ott K, Fink U, Becker K, Stahl A, Dittler H, Busch R, Stein H, Lordick F, Link T, Schwaiger M, Siewert J, Weber WA. Prediction of Response to Preoperative Chemotherapy in Gastric Carcinoma by Metabolic Imaging: Results of a Prospective Trial. JCO 2003;21:4604-10. [DOI: 10.1200/jco.2003.06.574] [Cited by in Crossref: 250] [Cited by in F6Publishing: 210] [Article Influence: 13.2] [Reference Citation Analysis]
143 Becker K, Mueller JD, Schulmacher C, Ott K, Fink U, Busch R, Böttcher K, Siewert JR, Höfler H. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-1530. [PMID: 14508841 DOI: 10.1002/cncr.11660] [Cited by in Crossref: 401] [Cited by in F6Publishing: 419] [Article Influence: 21.1] [Reference Citation Analysis]
144 Xiong HQ, Gunderson LL, Yao J, Ajani JA. Chemoradiation for resectable gastric cancer. Lancet Oncol. 2003;4:498-505. [PMID: 12901965 DOI: 10.1016/s1470-2045(03)01170-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
145 Reichle A, Bolder U, Bataille F, Messmann H, Wagner H, Zaiss M, Wild P, Hofstädter F, Andreesen R, Jauch KW. A multimodal treatment approach including high-dose chemotherapy in very advanced gastric cancer: evidence for control of metastatic disease. Bone Marrow Transplant 2003;32:665-71. [PMID: 13130313 DOI: 10.1038/sj.bmt.1704203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
146 Baba H, Yamamoto M, Endo K, Ikeda Y, Toh Y, Kohnoe S, Okamura T. Clinical efficacy of S-1 combined with cisplatin for advanced gastric cancer. Gastric Cancer. 2003;6 Suppl 1:45-49. [PMID: 12775020 DOI: 10.1007/s10120-003-0222-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
147 Janunger KG, Hafström L, Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis. Eur J Surg. 2002;168:597-608. [PMID: 12699095 DOI: 10.1080/11024150201680005] [Cited by in Crossref: 152] [Cited by in F6Publishing: 145] [Article Influence: 8.0] [Reference Citation Analysis]
148 Mercer SJ, Somers SS, Knight LA, Whitehouse PA, Sharma S, Nicolantonio FD, Glaysher S, Toh S, Cree IA. Heterogeneity of chemosensitivity of esophageal and gastric carcinoma: . Anti-Cancer Drugs 2003;14:397-403. [DOI: 10.1097/00001813-200307000-00002] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
149 Menges M, Schmidt C, Lindemann W, Ridwelski K, Pueschel W, Jüngling B, Feifel G, Schilling M, Stallmach A, Zeitz M. Low toxic neoadjuvant cisplatin, 5-fluorouracil and folinic acid in locally advanced gastric cancer yields high R-0 resection rate. J Cancer Res Clin Oncol 2003;129:423-9. [PMID: 12836016 DOI: 10.1007/s00432-003-0467-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
150 Roth AD, Allal AS, Bründler MA, de Peyer R, Mermillod B, Morel P, Huber O. Neoadjuvant radiochemotherapy for locally advanced gastric cancer: a phase I-II study. Ann Oncol. 2003;14:110-115. [PMID: 12488302 DOI: 10.1093/annonc/mdg023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 1.6] [Reference Citation Analysis]
151 Kodera Y, Schwarz RE, Nakao A. Extended lymph node dissection in gastric carcinoma. Journal of the American College of Surgeons 2002;195:855-64. [DOI: 10.1016/s1072-7515(02)01496-5] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 2.9] [Reference Citation Analysis]
152 Nitti D, Belluco C, Mammano E, Marchet A, Ambrosi A, Mencarelli R, Segato P, Lise M. Low level of p27(Kip1) protein expression in gastric adenocarcinoma is associated with disease progression and poor outcome. J Surg Oncol 2002;81:167-76. [DOI: 10.1002/jso.10172] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.6] [Reference Citation Analysis]
153 Yao J, Ajani J. Therapy of localized gastric cancer: preoperative and postoperative approaches. Annals of Oncology 2002;13:7-12. [DOI: 10.1093/annonc/mdf632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
154 Tschmelitsch J, Weiser MR, Karpeh MS. Modern staging in gastric cancer. Surg Oncol. 2000;9:23-30. [PMID: 11525303 DOI: 10.1016/S0960-7404(00)00020-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 0.8] [Reference Citation Analysis]
155 Weber WA, Ott K, Becker K, Dittler HJ, Helmberger H, Avril NE, Meisetschläger G, Busch R, Siewert JR, Schwaiger M, Fink U. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65. [PMID: 11408502 DOI: 10.1200/JCO.2001.19.12.3058] [Cited by in Crossref: 521] [Cited by in F6Publishing: 442] [Article Influence: 24.8] [Reference Citation Analysis]
156 Lowy AM, Feig BW, Janjan N, Rich TA, Pisters PWT, Ajani JA, Mansfield PF. A Pilot Study of Preoperative Chemoradiotherapy for Resectable Gastric Cancer. Ann Surg Oncol 2001;8:519-24. [DOI: 10.1007/s10434-001-0519-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 68] [Article Influence: 3.3] [Reference Citation Analysis]
157 Onaitis MW, Noone RB, Hartwig M, Hurwitz H, Morse M, Jowell P, McGrath K, Lee C, Anscher MS, Clary B, Mantyh C, Pappas TN, Ludwig K, Seigler HF, Tyler DS. Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. Ann Surg. 2001;233:778-785. [PMID: 11371736 DOI: 10.1097/00000658-200106000-00007] [Cited by in Crossref: 105] [Cited by in F6Publishing: 104] [Article Influence: 5.0] [Reference Citation Analysis]
158 Bozzetti F, Bignami P, Bertario L, Fissi S, Eboli M. Surgical treatment of gastric cancer invading the oesophagus. Eur J Surg Oncol. 2000;26:810-814. [PMID: 11087650 DOI: 10.1053/ejso.2000.1009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
159 Sun W, Haller DG. Recent Advances in the Treatment of Gastric Cancer: . Drugs 2001;61:1545-51. [DOI: 10.2165/00003495-200161110-00002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 0.9] [Reference Citation Analysis]
160 Stein HJ, Sendler A, Fink U, Siewert JR. Multidisciplinary approach to esophageal and gastric cancer. Surg Clin North Am. 2000;80:659-682; discussions 683-686. [PMID: 10836011 DOI: 10.1016/s0039-6109(05)70205-x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 48] [Article Influence: 2.6] [Reference Citation Analysis]
161 Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced Staging and All Chemotherapy Preoperatively in Patients with Potentially Resectable Gastric Carcinoma. JCO 1999;17:2403-2403. [DOI: 10.1200/jco.1999.17.8.2403] [Cited by in Crossref: 71] [Cited by in F6Publishing: 66] [Article Influence: 3.1] [Reference Citation Analysis]
162 Niederhuber JE. Neoadjuvant therapy. Ann Surg 1999;229:309-12. [PMID: 10077041 DOI: 10.1097/00000658-199903000-00002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]